Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer | 598k | -- | 1960 |
| Ms. Mali Zeevi CPA, CPA | Chief Financial Officer | 374k | -- | 1976 |
| Dr. Ella Sorani Ph.D. | Chief Development Officer | 452k | -- | 1968 |
| Ms. Holly W. May M.B.A. | President of BioLineRx USA | 710k | -- | 1962 |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations | -- | -- | -- |
| Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor | -- | -- | -- |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director | -- | -- | -- |
BioLineRx Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 79
Description
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Corporate Governance
Upcoming Events
February 4, 2025 at 12:00 PM UTC - February 9, 2025 at 12:00 PM UTC
BioLineRx Ltd. Earnings Date
Recent Events
Recent Events Information Not Available